{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-057745","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.287484+00:00","generated_at":"2026-06-09T00:41:39.690903+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio Q3 net loss $177M; acoramidis NDA filing by year-end","bullets":["Net loss attributable to common stockholders $177M ($1.08 per share) vs $137M ($0.93) YoY.","Revenue $4.1M, up from $0.3M YoY; operating costs $161.8M vs $129.5M.","Cash, equivalents, marketable securities $505.2M; raised $316M gross via ATM and PIPE.","NDA for acoramidis (ATTR-CM) to be filed with FDA by end of 2023; Phase 3 win ratio 1.8 (p<0.0001).","Regulatory alignment with FDA/EMA for infigratinib in achondroplasia; Phase 3 trial start expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-057745","json":"https://secwatch.observer/filing/0000950170-23-057745.json","markdown":"https://secwatch.observer/filing/0000950170-23-057745.md","text":"https://secwatch.observer/filing/0000950170-23-057745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000095017023057745/0000950170-23-057745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000095017023057745/bbio-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:41:39.690903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab9a29707e09927b906d93c81267a00c947199f8","claim":"BridgeBio Pharma, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 2, 2023, BridgeBio Pharma, Inc. reported recent business updates and its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017023057745/0000950170-23-057745-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}